Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Pediatric Oncology
•
Leukemia
•
Hematology
What is the role of post-transplant FLT3 inhibition given the results of BMT-CTN 1506 (MORPHO)?
Related Questions
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
For AML patients, when do you stop antiinfective agents?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
